St. Louis, Mo. — August 27, 2025 — Leads & Copy — Wugen, Inc., a clinical-stage biotechnology company, announced the closing of $115 million equity financing led by Fidelity Management & Research Company, with participation from RiverVest Venture Partners, Lightchain Capital, Abingworth, ICG, LYZZ Capital, Tybourne Capital Management, Aisling Capital Management, and other investors.
The financing will advance the pivotal T-RRex study of WU-CART-007 in relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). WU-CART-007, also known as soficabtagene geleucel, is a CD7-targeted, CRISPR-edited allogeneic CAR-T cell therapy with potential to be the first approved “off-the-shelf” CAR-T for T-cell malignancies.
In a Phase 1/2 study, WU-CART-007 achieved an overall response rate (ORR) of 91% and a composite complete remission (CRc) rate of 73% at the recommended Phase 2 dose. A BLA filing is targeted for 2027.
Kumar Srinivasan, Ph.D., MBA, is the president and chief executive officer of Wugen. Cherry Thomas, M.D., is the chief medical officer of Wugen. Niall O’Donnell, Ph.D., is the Managing Director at RiverVest.
Investor Contact: Mark Lewis, Ph.D. at Mlewis@wugen.com or 314-501-1968. Media Contact: Cory Tromblee at cory@scientpr.com
Source: Wugen, Inc.
